Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mirati Therapeutics
(NQ:
MRTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Mirati Therapeutics
< Previous
1
2
3
4
5
6
7
Next >
Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT
October 06, 2021
Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron. Related: Merck Seals Acceleron Pharma Deal...
Via
Benzinga
What 6 Analyst Ratings Have To Say About Mirati Therapeutics
September 23, 2021
Over the past 3 months, 6 analysts have published their opinion on Mirati Therapeutics (NASDAQ:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
September 23, 2021
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:
Via
Benzinga
Expert Ratings For Mirati Therapeutics
September 21, 2021
Over the past 3 months, 5 analysts have published their opinion on Mirati Therapeutics (NASDAQ:
Via
Benzinga
New CEO At Mirati Therapeutics
September 20, 2021
Amid data readouts from adagrasib, sitravatinib programs, Mirati Therapeutics Inc (NASDAQ: MRTX) has appointed David Meek as Chief Executive Officer,...
Via
Benzinga
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
September 21, 2021
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
September 21, 2021
RBC Capital boosted MSCI Inc. (NYSE:MSCI) price tar...
Via
Benzinga
Why Mirati Therapeutics Is A Dangerous Rival To Amgen In Colon Cancer
September 20, 2021
Mirati Therapeutics easily beat Amgen's test results in colon cancer.
Via
Investor's Business Daily
Why Mirati Therapeutics Stock Is Trading Higher Today
September 20, 2021
Mirati Therapeutics Inc (NASDAQ: MRTX) is trading higher Monday after the company announced clinical data with investigational adagrasib as monotherapy and in combination...
Via
Benzinga
35 Stocks Moving In Monday's Mid-Day Session
September 20, 2021
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday. Edesa Biotech, Inc. (NASDAQ: EDSA) jumped 30.6% to $7.68 after the company...
Via
Benzinga
Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients
September 20, 2021
Mirati Therapeutics Inc (NASDAQ: MRTX) has announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500 of sitravatinib combined...
Via
Benzinga
Mirati Posts Adagrasib Data In KRAS-Mutated Lung Cancer, FDA Filing Now On The Cards
September 20, 2021
After data readout from KRAS drug adagrasib in colon cancer, Mirati Therapeutics Inc (NASDAQ: MRTX) has announced positive topline results from a Phase...
Via
Benzinga
Exposures
Product Safety
Mirati Showcases New KRAS Drug Data In Colorectal Cancer At ESMO
September 20, 2021
Mirati Therapeutics Inc (NASDAQ: MRTX) announced results from the 600mg BID dose cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib in heavily...
Via
Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
September 19, 2021
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical...
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2021
August 26, 2021
Upgrades Scotiabank upgraded the previous rating for Enerplus Corp (NYSE:
Via
Benzinga
Mirati's KRAS Inhibitor Receives FDA Breakthrough Tag For Lung Cancer Harboring KRAS Mutation
June 25, 2021
The FDA has granted Breakthrough Therapy designation to Mirati Therapeutics Inc's (NASDAQ: MRTX) adagrasib in non-small cell lung cancer (NSCLC) patients...
Via
Benzinga
Exposures
Product Safety
20 Stocks Moving in Friday's Pre-Market Session
June 25, 2021
Gainers Fuwei Films (Holdings) Co., Ltd. (NASDAQ: FFHL) rose 83.4% to $16.34 in pre-market trading after the company reported a sharp rise in Q1 earnings and sales. Grove, Inc. (...
Via
Benzinga
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
June 25, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ...
Via
Benzinga
Exposures
COVID-19
A Peek Into The Markets: US Stock Futures Up Following Thursday's Rally; Nike Posts Upbeat Results
June 25, 2021
Pre-open movers U.S. stock futures traded higher in early pre-market trade. The Dow Jones surged more than 300 points, while the S&P 500 closed at a record high in the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
7 Stocks Moving In Thursday's After-Hours Session
June 24, 2021
Gainers Mirati Therapeutics (NASDAQ: MRTX) shares are trading higher after the company announced it received Breakthrough Therapy Designation from the FDA for patients with...
Via
Benzinga
Exposures
Product Safety
14 Biotech Stocks To Watch Over The Next 6 Months
June 23, 2021
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:...
Via
Benzinga
Week In Review: Zai Lab Enters $338 Million Agreement To In-License KRAS Inhibitor
June 05, 2021
Shanghai's Zai Lab in-licensed Greater China rights to adagrasib, a KRASG12C inhibitor, from Mirati of San Diego in a $338 million agreement. Mirati will receive a $65 million upfront payment and up to...
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For June 4, 2021
June 04, 2021
Upgrades According to Argus Research, the prior rating for Diageo PLC (NYSE:DEO) was changed from Hold to Buy. The current stock performance of Diageo shows a 52-week-high...
Via
Benzinga
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing
May 26, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2021
May 17, 2021
Upgrades B of A Securities upgraded the previous rating for Kosmos Energy Ltd (NYSE:KOS) from Neutral to Buy. In the first quarter, Kosmos Energy showed an EPS of $0.08,...
Via
Benzinga
10 Biggest Price Target Changes For Monday
May 17, 2021
Morgan Stanley boosted the price target on Applied Materials, Inc. (NASDAQ: AMAT) from $113 to $137. Applied Materials shares fell 1.1% to $123.46 in pre-market trading....
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2021
May 10, 2021
Upgrades Barrington Research upgraded the previous rating for ViacomCBS Inc (NASDAQ:VIAC) from Market Perform to Outperform. For the first quarter, ViacomCBS had an EPS of...
Via
Benzinga
10 Biggest Price Target Changes For Monday
May 10, 2021
BMO Capital boosted The Middleby Corporation (NASDAQ: MIDD) price target from $225 to $250. Middleby shares rose 1.9% to close at $182.83 on Friday. Atlantic Equities reduced...
Via
Benzinga
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
April 10, 2021
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.